Published in Heart on March 01, 1997
[Commentary on the guidelines the diagnosis and the therapy of syncope--the European Society of Cardiology 2001 and the update 2004]. Z Kardiol (2005) 0.95
Current Management of Syncope: Treatment Alternatives. Curr Treat Options Cardiovasc Med (2004) 0.80
Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. Heart (1998) 0.75
Clinical efficacy of beta1 selective adrenergic blockers in the treatment of neurocardiogenic syncope - a meta-analysis. Clin Pharmacol (2010) 0.75
Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole. N Engl J Med (1993) 4.48
Diagnostic evaluation of syncope. Am J Med (1991) 2.27
Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin. Am J Med (1991) 2.16
Head-upright tilt-table testing in evaluation and management of the malignant vasovagal syndrome. Am J Cardiol (1992) 1.82
Differentiation of convulsive syncope and epilepsy with head-up tilt testing. Ann Intern Med (1991) 1.72
The usefulness of head-up tilt testing and hemodynamic investigations in the workup of syncope of unknown origin. Pacing Clin Electrophysiol (1988) 1.43
Unexplained syncope evaluated by electrophysiologic studies and head-up tilt testing. Ann Intern Med (1991) 1.40
Permanent pacing for cardioinhibitory malignant vasovagal syndrome. Br Heart J (1994) 1.28
Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope. Circulation (1996) 1.23
Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol (1990) 1.17
Provocation of hypotension during head-up tilt testing in subjects with no history of syncope or presyncope. Circulation (1995) 1.12
Clonidine raises blood pressure in severe idiopathic orthostatic hypotension. Am J Med (1983) 1.07
Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results. Am Heart J (1995) 1.03
Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients with neurocardiogenic syncope. J Am Coll Cardiol (1992) 1.01
Inhibition of efferent sympathetic nerve activity by 5-hydroxytryptophan and centrally administered 5-hydroxytryptamine. Neuropharmacology (1975) 0.95
Central depression of carotid baroreceptor pressor response, arterial pressure and heart rate by 5-hydroxytryptophan: influence of supracollicular areas of the brain. J Pharmacol Exp Ther (1977) 0.86
Reproducibility of isoproterenol tilt-table tests in patients with syncope. Am J Cardiol (1992) 0.85
Reproducibility of head upright tilt table test results in patients with syncope. Pacing Clin Electrophysiol (1992) 0.84
In vivo microdialysis evidence for central serotonin1A and serotonin1B autoreceptor blocking properties of the beta adrenoceptor antagonist (-)penbutolol. J Pharmacol Exp Ther (1993) 0.82
Reproducibility of head-up tilt-table testing for eliciting susceptibility to neurally mediated syncope in patients without structural heart disease. Am J Cardiol (1992) 0.82
Prolonged asystole during head-up tilt table testing after beta blockade. Pacing Clin Electrophysiol (1992) 0.81
(-)-Penbutolol as a blocker of central 5-HT1A receptor-mediated responses. Eur J Pharmacol (1992) 0.80
Left superior vena cava persistence in patients undergoing pacemaker or cardioverter-defibrillator implantation: a 10-year experience. Chest (2001) 5.12
The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med (1995) 4.61
Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med (2000) 4.04
Ambulatory 24-hr pH monitoring of esophagus, fundus, and antrum. A new technique for simultaneous study of gastroesophageal and duodenogastric reflux. Dig Dis Sci (1990) 1.76
Asthma severity and medical resource utilisation. Eur Respir J (2004) 1.74
Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J (2004) 1.66
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol (1992) 1.66
Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation (1994) 1.61
Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart (2005) 1.57
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant (2005) 1.55
Wide spectrum of presentation and variable outcomes of isolated left ventricular non-compaction. Heart (2006) 1.53
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens (1998) 1.46
Antiarrhythmic benefits of dual chamber stimulation with rate-response in patients with paroxysmal atrial fibrillation and chronotropic incompetence: a prospective, multicentre study. Europace (1999) 1.41
Coronary stenting with the half (disarticulated) Palmaz-Schatz stent: immediate results and six-month follow-up. Cathet Cardiovasc Diagn (1997) 1.40
[Diagnostic contribution of magnetic resonance in clinically suspected arrhythmogenic dysplasia of the right ventricle]. G Ital Cardiol (1996) 1.39
Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomuscular phenotypes. J Med Genet (2003) 1.13
Nightmares and sleep disturbances with simvastatin and metoprolol. Ann Pharmacother (2001) 1.12
Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol (1993) 1.10
A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol (1994) 1.09
Clinical results of the Verapamil inHypertension and Atherosclerosis Study. VHAS Investigators. J Hypertens (1997) 1.09
Randomized crossover comparison of right atrial appendage pacing versus interatrial septum pacing for prevention of paroxysmal atrial fibrillation in patients with sinus bradycardia. Am Heart J (2001) 1.09
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J (1999) 1.07
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens (1998) 1.06
A novel Alu-like element rearranged in the dystrophin gene causes a splicing mutation in a family with X-linked dilated cardiomyopathy. Am J Hum Genet (1998) 1.06
Opposite effects of interleukin 10 common gene polymorphisms in cardiovascular diseases and in successful ageing: genetic background of male centenarians is protective against coronary heart disease. J Med Genet (2004) 1.04
Pulmonary arterial hypertension associated to connective tissue diseases. Lupus (2005) 1.03
Laminopathies: many diseases, one gene. Report of the first Italian Meeting Course on Laminopathies. Acta Myol (2011) 1.01
Amlodipine reduces transient myocardial ischemia in patients with coronary artery disease: double-blind Circadian Anti-Ischemia Program in Europe (CAPE Trial). J Am Coll Cardiol (1994) 1.00
N-acetylcysteine reduces methemoglobin in vitro. Ann Emerg Med (1996) 1.00
Reliability of 24-hour home esophageal pH monitoring in diagnosis of gastroesophageal reflux. Dig Dis Sci (1989) 1.00
Dynamic electrophysiological behavior of human atria during paroxysmal atrial fibrillation. Circulation (1995) 0.99
Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol (1994) 0.99
Benefits in projected pacemaker longevity and in pacing related costs conferred by automatic threshold tracking. Pacing Clin Electrophysiol (2000) 0.99
Genetic effects of PR toxin in eukaryotic microorganisms. Environ Mutagen (1979) 0.98
Evaluation of the pulse-contour method of determining stroke volume in man. Circulation (1972) 0.98
Atrial premature beats coupling interval determines lone paroxysmal atrial fibrillation onset. Int J Cardiol (1992) 0.97
Transvenous low energy internal cardioversion for atrial fibrillation: a review of clinical applications and future developments. Pacing Clin Electrophysiol (2001) 0.96
Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med (1997) 0.94
Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol (1995) 0.92
Persistent left fifth aortic arch associated with tetralogy of Fallot. Pediatr Cardiol (1997) 0.92
Clinical value of multidetector CT coronary angiography as a preoperative screening test before non-coronary cardiac surgery. Heart (2006) 0.92
Atherosclerosis and calcium antagonists: the VHAS. The Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators. J Hum Hypertens (1992) 0.92
Increased intralymphocytic sodium content in essential hypertension: an index of impaired Na+ cellular metabolism. Clin Sci (Lond) (1981) 0.91
Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols. Pacing Clin Electrophysiol (1998) 0.91
Impact of consistent atrial pacing algorithm on premature atrial complexe number and paroxysmal atrial fibrillation recurrences in brady-tachy syndrome: a randomized prospective cross over study. J Interv Card Electrophysiol (2001) 0.91
Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin. Br Heart J (1990) 0.90
Captopril in mild heart failure: preliminary observations of a long-term, double-blind, placebo-controlled multicentre trial. Postgrad Med J (1986) 0.90
[Paroxysmal atrial fibrillation: study of the pattern of onset using dynamic electrocardiography]. Cardiologia (1989) 0.89
Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med (2001) 0.88
Effects of a low-salt diet and of acute salt loading on blood pressure and intralymphocytic sodium concentration in young subjects with borderline hypertension. Clin Sci (Lond) (1981) 0.87
Effects of moderate salt restriction on intralymphocytic sodium and pressor response to stress in borderline hypertension. Hypertension (1983) 0.87
Platelet and neutrophil activation during cardiac surgical procedures: impact of cardiopulmonary bypass. Ann Thorac Surg (1998) 0.87
Neonatal aortic arch thrombosis as a result of congenital cytomegalovirus infection. Pediatrics (2001) 0.86
Genetic and metabolic effects of gluconasturtiin, a glucosinolate derived from cruciferae. Mutat Res (2004) 0.86
On the mechanism by which saxitoxin binds to and blocks sodium channels. Ann N Y Acad Sci (1986) 0.86
[Monitoring esophageal pressure: comparison of various methods and a unique solution]. Minerva Chir (1991) 0.85
Paroxysmal atrial fibrillation in sleep. Sleep (1997) 0.85
Autocrine and intracrine signaling for cardiogenesis in embryonic stem cells: a clue for the development of novel differentiating agents. Handb Exp Pharmacol (2006) 0.85
Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest (1998) 0.85
Interplay between methylenetetrahydrofolate reductase gene polymorphism 677C-->T and serum folate levels in determining hyperhomocysteinemia in heart transplant recipients. J Heart Lung Transplant (2001) 0.85
On the value of the activated clotting time for monitoring heparin therapy in acute coronary syndromes. Am J Cardiol (1993) 0.85
Idiopathic restrictive cardiomyopathy in the young: report of two cases. Int J Cardiol (1990) 0.85
An electromyographic study of the vastii muscles during open and closed kinetic chain submaximal isometric exercises. Int J Sports Phys Ther (2012) 0.84
Evaluation by cardiopulmonary exercise test of DDDR versus DDD pacing. Pacing Clin Electrophysiol (1992) 0.84
Interleukin-6 gene polymorphism is an age-dependent risk factor for myocardial infarction in men. Int J Immunogenet (2005) 0.84
Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin's disease patients. Haematologica (1996) 0.84
Efficacy and tolerability in fully conscious patients of transvenous low-energy internal atrial cardioversion for atrial fibrillation. Am J Cardiol (1998) 0.84
Snoring every night as a risk factor for myocardial infarction: a case-control study. BMJ (1990) 0.84
Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. Heart (2002) 0.83
Low energy internal atrial cardioversion in atrial fibrillation lasting more than a year. Pacing Clin Electrophysiol (1999) 0.83
[Tetralogy of Fallot associated with total anomalous pulmonary venous drainage. Case report (author's transl)]. G Ital Cardiol (1980) 0.83
[Visceral and ocular Larva migrans: epidemiologic study, clinical and immunologic findings on 20 cases, adult and child]. Bull Soc Pathol Exot Filiales (1989) 0.83
Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest (1995) 0.83